| Literature DB >> 20705559 |
Andres Forero-Torres1, Mansoor N Saleh, Janice A Galleshaw, Cheryl F Jones, Jatin J Shah, Ivor J Percent, Lisle M Nabell, John T Carpenter, Carla I Falkson, Helen Krontiras, Marshall M Urist, Kirby I Bland, Jennifer F De Los Santos, Ruby F Meredith, Valerie Caterinicchia, Wanda K Bernreuter, Janis P O'Malley, Yufeng Li, Albert F LoBuglio.
Abstract
INTRODUCTION: Tumor content or expression of vascular endothelial growth factor (VEGF) is associated with impaired efficacy of antiestrogen adjuvant therapy. We designed a pilot study to assess the feasibility and short-term efficacy of neoadjuvant letrozole and bevacizumab (anti-VEGF) in postmenopausal women with stage II and III estrogen receptor/progesterone receptor-positive breast cancer. PATIENTS AND METHODS: Patients were treated with a neoadjuvant regimen of letrozole orally 2.5 mg/day and bevacizumab intravenously 15 mg/kg every 3 weeks for a total of 24 weeks before the surgical treatment of their breast cancer. Patients were followed for toxicity at 3-week intervals, and tumor assessment (a physical examination and ultrasound) was performed at 6-week intervals. Positron emission tomography (PET) scans were performed before therapy and 6 weeks after the initiation of therapy.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20705559 PMCID: PMC4451110 DOI: 10.3816/CBC.2010.n.035
Source DB: PubMed Journal: Clin Breast Cancer ISSN: 1526-8209 Impact factor: 3.225